Thus, the more likely explanation for the reduced Aβ42 levels in a subgroup of sCJD patients seems to be a combined effect of age-related co-morbidity, influenced by the APOE genotype, and the effect of neuronal loss which can be very significant in CJD even a few months after clinical onset. This evidence concerns the gene APOE and Creutzfeldt Jacob disease.